Emerging treatment strategies for COVID-19 infection

M Gavriatopoulou, I Ntanasis-Stathopoulos… - Clinical and …, 2021 - Springer
The new type of coronavirus (COVID-19), SARS-CoV-2 originated from Wuhan, China and
has led to a worldwide pandemic. COVID-19 is a novel emerging infectious disease caused …

Reducing aerosol-related risk of transmission in the era of COVID-19: an interim guidance endorsed by the International Society of Aerosols in Medicine

JB Fink, S Ehrmann, J Li, P Dailey… - Journal of aerosol …, 2020 - liebertpub.com
National and international guidelines recommend droplet/airborne transmission and contact
precautions for those caring for coronavirus disease 2019 (COVID-19) patients in …

Transmission of pathogen-laden expiratory droplets in a coach bus

X Yang, C Ou, H Yang, L Liu, T Song, M Kang… - Journal of hazardous …, 2020 - Elsevier
Droplet dispersion carrying viruses/bacteria in enclosed/crowded buses may induce
transmissions of respiratory infectious diseases, but the influencing mechanisms have been …

[HTML][HTML] Nebulised delivery of RNA formulations to the lungs: From aerosol to cytosol

MT Neary, LM Mulder, PS Kowalski… - Journal of Controlled …, 2024 - Elsevier
In the past decade RNA-based therapies such as small interfering RNA (siRNA) and
messenger RNA (mRNA) have emerged as new and ground-breaking therapeutic agents for …

Practical strategies to reduce nosocomial transmission to healthcare professionals providing respiratory care to patients with COVID-19

R Kaur, TT Weiss, A Perez, JB Fink, R Chen, F Luo… - Critical Care, 2020 - Springer
Abstract Coronavirus disease (COVID-19) is an emerging viral infection that is rapidly
spreading across the globe. SARS-CoV-2 belongs to the same coronavirus class that …

Advances in pulmonary drug delivery

A Yıldız-Peköz, C Ehrhardt - Pharmaceutics, 2020 - mdpi.com
Pulmonary drug delivery represents an attractive, non-invasive administration option. In
addition to locally acting drugs, molecules that are intended to produce systemic effects can …

Guideline for the management of COVID-19 patients during hospital admission in a non-intensive care setting

K Nielsen Jeschke, B Bonnesen… - European Clinical …, 2020 - Taylor & Francis
ABSTRACT Introduction Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
has presented health-care systems worldwide with novel challenges and experiences and …

Nebuliser type influences both patient-derived bioaerosol emissions and ventilation parameters during mechanical ventilation

M Joyce, JA McGrath, M Mac Giolla Eain, A O'Sullivan… - Pharmaceutics, 2021 - mdpi.com
COVID-19 may lead to serious respiratory complications which may necessitate ventilatory
support. There is concern surrounding potential release of patient-derived bioaerosol during …

Investigation of fugitive aerosols released into the environment during high-flow therapy

JA McGrath, C O'Toole, G Bennett, M Joyce, MA Byrne… - Pharmaceutics, 2019 - mdpi.com
Background: Nebulised medical aerosols are designed to deliver drugs to the lungs to aid in
the treatment of respiratory diseases. However, an unintended consequence is the potential …

Inhaled nano-based therapeutics for inflammatory lung diseases: Recent advances and future prospects

N Gulati, DK Chellappan, R MacLoughlin, K Dua… - Life Sciences, 2021 - Elsevier
Inflammatory lung diseases related morbidity and mortality impose a significant financial
burden. Inflammation is a hallmark of many diseases of the respiratory system which is …